NeuroEM Therapeutics

NeuroEM Therapeutics is pioneering a first-in-class, non-invasive medical device for Alzheimer's disease, having received FDA Breakthrough Device designation. Its MemorEM device administers transcranial electromagnetic waves (TEMT-RF) to disaggregate toxic beta-amyloid and p-tau oligomers, rebalance the immune system, and boost cellular energy in the brain. The company has reported promising Phase 2 data showing cognitive reversal in a majority of patients and is preparing for pivotal trials. NeuroEM represents a significant shift from pharmaceutical approaches to a technology-driven, at-home treatment paradigm for neurodegenerative diseases.

Transcranial Electromagnetic Treatment leveraging Radio Frequencies (TEMT-RF), a non-invasive neuromodulation technology delivered via a wearable head device to disaggregate toxic protein oligomers, rebalance the immune system, and boost neuronal energy production.

NeuroEM competes in the Alzheimer's therapeutic space dominated by pharmaceutical companies, including Biogen/Eisai (Leqembi), Lilly (Donanemab), and others developing anti-amyloid antibodies and novel small molecules. Its primary differentiation is its non-invasive, drug-free, device-based approach that targets multiple disease mechanisms simultaneously, positioning it as a potential alternative or adjunct to pharmacologic therapies.